United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Results From a Global Phase 3 Trial Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Leonard H van den Berg, MD, PhD (Presenter)
Published: American Academy of Neurology Annual Meeting 2024
Date: April 13 - 18, 2024
ORION: A Global, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy
Lead Author: Günter Höglinger, MD (Presenter)
Published: AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
Date: March 5 - 9, 2024
Findings From a Pharmacokinetic and Pharmacodynamic Study of Sodium Phenylbutyrate and Taurursodiol in Participants With Amyotrophic Lateral Sclerosis
Lead Author: James Wymer, MD (Presenter)
Published: 2024 MDA Clinical & Scientific Conference (MDA)
Date: March 3 - 6, 2024
Next Steps in Development for AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen
Published: 2024 MDA Clinical & Scientific Conference (MDA)
Date: March 3 - 6, 2024
A Joint Model for Assessing Mortality-Adjusted Progression (MAP) in Amyotrophic Lateral Sclerosis: Application to Clinical Trials of Sodium Phenylbutyrate and Taurursodiol
Lead Author: Ruben van Eijk
Published: International Symposium on ALS/MND (MNDA)
Date: December 6 - 8, 2023
Effect of Sodium Phenylbutyrate and Taurursodiol on Plasma Concentrations of Neuroinflammatory Biomarkers in Amyotrophic Lateral Sclerosis: Results From the CENTAUR Trial
Lead Author: Robert Bowser, PhD & Jiyan An
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: December 2, 2023
Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations
Lead Author: Sara Öhrman (Presenter)
Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Date: November 12 - 15, 2023
Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease
Lead Author: Lahar Mehta, MD (Presenter)
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: October 24 - 27, 2023
Design of a Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009 ORION)
Lead Author: Günter Höglinger, MD
Published: Neuro2023
Date: October 19 - 20, 2023
Analysis of Sodium Phenylbutyrate and Taurursodiol Survival Effect in ALS Using External Controls
Lead Author: Sabrina Paganoni, MD, PhD & Melanie Quintana, PhD
Published: Annals of Clinical and Translational Neurology
Date: October 9, 2023